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Abstract
Background: The optimal treatment regimen and duration of the therapy is still controversial in
spinal brucellosis. The aim of this study is to compare the efficacy, adverse drug reactions,
complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the
treatment of spinal brucellosis.
Methods: The patients diagnosed as spinal brucellosis between January 2002 to December 2004
were enrolled into the study. Patients were enrolled into the two antimicrobial therapy groups
(doxycycline plus streptomycin vs. ciprofloxacin plus rifampicin) consecutively. For the cost analysis
of the two regimens, only the cost of antibiotic therapy was analysed for each patient.
Results: During the study period, 31 patients with spinal brucellosis were enrolled into the two
antimicrobial therapy groups. Fifteen patients were included in doxycycline plus streptomycin
group and 16 patients were included in ciprofloxacin plus rifampicin group. Forty-two levels of
spinal column were involved in 31 patients. The most common affected site was lumbar spine (n =
32, 76%) and involvement level was not different in two groups. Despite the disadvantages (older
age, more prevalent operation and abscess formation before the therapy) of the patients in the
ciprofloxacin plus rifampicin group, the duration of the therapy (median 12 weeks in both groups)
and clinical response were not different from the doxycycline plus streptomycin. The cost of
ciprofloxacin plus rifampicin therapy was 1.2 fold higher than the cost of doxycycline plus
streptomycin therapy.
Conclusion: Classical regimen (doxycycline plus streptomycin), with the appropriate duration (at
least 12 weeks), is still the first line antibiotics and alternative therapies should be considered when
adverse drug reactions were observed.
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Human brucellosis is a worldwide zoonosis and affects
over 500 000 people yearly in non-industrialized coun-
tries of the world. It is still public health problem in most
countries of Mediterranean, including Turkey, Balkan, the
Middle East and Central and South America [1].
Brucellosis is a systemic disease and may involve any
organ system. However, osteoarticular involvement is the
most common complication of brucellosis and the
reported incidence is 10–85% in most series [2-7]. Spinal
column is one of the most frequently affected site in oste-
oarticular brucellosis. However its incidence is highly var-
iable (2–54%) in different studies, depending on the
study population, the species of Brucella involved and the
difficulty of diagnosis [3-8]. On the other hand, the opti-
mal treatment regimen and duration of the therapy is still
controversial in osteoarticular involvement including spi-
nal brucellosis. The combination of doxycycline with
streptomycin is accepted to be the most effective regimen
in spinal brucellosis [1]. However, therapeutic failure and
relapse are still common. The risk of adverse drug reac-
tions is increased due to the prolonged use of these anti-
biotics and limited the therapy [4,9,10]. Other treatment
option, the combination of rifampicin and doxycycline,
are associated with worst outcomes [11,12]. In recent
years, fluoroquinolones has been shown to be effective
both in vitro and in vivo in the treatment of brucellosis
[13-19]. Furthermore, due to ability of fluoroquinolones
to penetrate and achieve increased concentration in the
tissues and their proven efficacy in bone and soft tissue
infections, the outcome may be better in spinal brucello-
sis. The regimens including fluoroquinolones may be an
alternative therapy to doxycycline and streptomycin.
The aim of this study is to compare the efficacy, adverse
drug reactions, complications and cost of ciprofloxacin
(C) plus rifampicin (R) versus doxycycline (D) plus strep-
tomycin (S) in the treatment of spinal brucellosis.
Methods
This study was planned as an open, controlled and non-
randomized. The Ethical Committee of Erciyes University
approved the study protocol used in this study. The
patients also accepted to take place in this study. The
patients diagnosed as spinal brucellosis between January
2002 to December 2004 were enrolled into two study
groups consecutively. Age less than 16 years, pregnancy,
neurobrucellosis, previous history of brucellosis and anti-
microbial therapy and discontinuation of the therapy for
any reason (allergy to any of the drugs, death, adverse
reactions) were exclusion criteria from the study.
Patients were enrolled into the two antimicrobial therapy
groups (DS vs. CR). Patients in DS group received doxcy-
cline, 100 mg twice a day orally for at least 12 weeks, plus
streptomycin, 1 g per day intramuscularly for 21 days (1 g
every other day for patients more than 60 years of age for
21 days). Patients in CR group received ciprofloxacin, 500
mg twice a day orally, plus rifampicin, 600 mg per day in
A) T2-weighted image shows increased signal intensity intervertebral disc space with epidural and prevertebral abscessFigure 1
A) T2-weighted image shows increased signal intensity intervertebral disc space with epidural and prevertebral abscess. B) T1-
weighted image shows irregularity and destruction of vertebral end plates with iso-to hyperintence signal intensity. C) T1-
weighted image after contrast injection shows increased signal intensity intervertebral disc space and the inferior and superior 
end plates of vertebral bodies. D) T1-weighted axial image shows epidural and paravertebral abscess with iso-to hyperintence 
signal intensity. E) T1-weighted axial image after contrast injection shows increased signal intensity epidural and paravertebral 
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therapy was prolonged according to clinical improvement
and the resolution of magnetic resonance imaging (MRI)
findings. The antibiotic therapy was changed if the
adverse effects of the drugs or therapeutic failure were
observed. If patient's complaints and findings were par-
tially improved and there was not an increase in MRI find-
ings at the end of 12 weeks, the therapy was prolonged
until resolving MRI findings. At least two weeks bed rest
was suggested to all patients and lumbosacral orthosis
was suggested to patients with pain due to instability. Fur-
thermore, the patients were followed up until 12 month
after cessation of the therapy for the evaluation of seque-
lae and relapse. For the cost analysis of the two regimens,
only the cost of antibiotic therapy was analysed for each
patient.
Clinical and laboratory evaluation
The patients were evaluated initially, at the end of the first
and second weeks, and monthly for six months and one
year after the therapy by two of the authors (EA and RKK).
Patients were examined for the therapeutic efficacy and
signs of drug toxicity by clinical data and laboratory stud-
ies; haemogram, differential leucocyte counts, erythrocyte
sedimentation rate (ESR), glucose, blood urine nitrogen
(BUN), creatinine, alanine aminotransferase, aspartate
aminotransferase, alkaline phophatase, bilirubin, albu-
min, total protein, electrolyte levels, C-reactive protein
(CRP), standard tube agglutination test for Brucella and
blood culture. At least two blood samples for culture were
taken initially.
Radiographic studies
All patients underwent MRI at the beginning of the treat-
ment and end of the treatment. MRI findings for brucello-
sis were decreased signal intensity in the vertebral bodies
on T1-weighted images, increased signal in the vertebral
bodies on T2-weighted images, increase in signal in discs
on T2 weighted images, loss of end-plate definition on T1
weighted images and contrast enhancement in the discs
on T1-weighted images with godolinuium (figure 1) [20].
Improvement was defined as lack of contrast enhance-
ment in the disc space (figure 2).
Microbiological studies
For agglutination tests, antigen of B. abortus S99 obtained
from Pendik Animal Diseases Research Institute (Istanbul,
Turkey) was used. A positive Wright test was taken as a
titer of 1/160 or greater. Blood culture specimens were
cultured by BACTEC 9240 system (Becton-Dickinson,
Mayland USA). Samples of blood were inoculated into
BACTEC system for 14 days. The isolates of Gram-negative
cocco-bacilli were identified by conventional biochemical
tests (e.g. motility, oxidase, catalase, glucose fermenta-
tion, production of H2S and urease) and also by an agglu-
tination test using antiserum obtained from patients
showing high titer of agglutination. Further identification
of Brucella strains was not performed.
A) T2-weighted image shows increased signal intensity involving subchondral part of L4 spine adjacent to L3-4 disk and decreased signal intensity intervertebral disc spaceFigure 2
A) T2-weighted image shows increased signal intensity involving subchondral part of L4 spine adjacent to L3-4 disk and 
decreased signal intensity intervertebral disc space. B) T1-weighted image shows iso-to hypointence signal intensity. C) T1-
weighted image after contrast injection shows decreased signal intensity intervertebral disc space. D) T1-weighted axial image 
shows paravertebral irregulary mass with iso-to hyperintence signal intensity. E) T1-weighted axial image after contrast injec-
tion shows increased signal intensity paravertebral mass.Page 3 of 10
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Brucellosis was defined by the clinical findings compati-
ble with brucellosis, positive standard tube agglutination
titer (1:160 or higher) and/or isolation of Brucella species
from blood, bone marrow or tissues [1]. Spinal brucello-
sis, including spondylitis, sacroiliitis and paraspinal
abscess, was diagnosed in the patient with brucellosis who
had MRI scan showing skeletal involvement characteristic
of osteomyelitis [2].
Brucellosis was categorized according to the length of
symptoms as acute (less than 8 weeks), subacute (from 8
to 52 weeks) or chronic (more than 1 year) [9].
Therapeutic failure was considered if symptoms and signs
of the disease persisted or increased, with increased MRI
findings, at the end of 12 weeks therapy [11].
Relapse was defined by the reappearance of symptoms or
signs of the disease or new positive blood cultures during
the 12 months after therapy [11].
Sequelae were considered to have occurred when pain,
abnormal physical findings or functional limitation per-
sisted for longer than six months posttherapy. The severity
of clinical sequelae was classified according to the
patient's functional status: normal, no pain or neurologi-
cal deficits remained; mild sequelae, no neurological def-
icits remained but pain with exercise that did not interfere
with work was present; moderate sequelae, pain interfered
with work or milder motor or sensorial deficits remained;
and severe sequelae, permanent and excruciating pain
(requiring rest and analgesics) or motor or sensorial defi-
cits remained [2].
Adverse effects that limited the therapy were; vomiting for
more than three consecutive days despite antiemetic ther-
apy, hepatotoxicity, defined as a >5-fold increase in the
aspartate or alanine aminotransferase level over the base-
line value or more than 10 times the upper limit of the
normal range; nephrotoxicity, defined as more than twice
the upper limit of the normal creatinine level range; oto-
toxicity, serious photosensitivity dermatitis manifested by
an exaggerated sunburn reaction, marked erythema with
edema or vesiculation or hypersensitivity reactions; cen-
tral nervous system toxicity, headache, dizziness, insom-
nia, hallucinations, seizures [12].
Operation indications were; to develop spinal instability,
cauda equina syndrome and severe weakness of muscle
due to extradural inflammatory mass or collapse of the
vertebral body [2,6]. Symptoms and sign that may be
indicative of clinical instability include low back pain
exacerbated with standing and lifting and relieved by
lying down. A sudden catch when extending from the
flexed to the straight posture is helpful in identifying
instability (21). A stability checklist was also developed
for the lumbar spine (Table 1). A point value total of 5 or
more indicates clinical instability (22).
Statistical analysis
Data were analysed by Statistical Package for the Social
Sciences (SPSS) version 10.0, × 2 test for qualitative varia-
bles, and Student's t test for quantitative variables.
Results
Patient characteristics
During the study period, a total of 405 patients of brucel-
losis were diagnosed and followed up in Erciyes Univer-
sity Hospital. Among these patients, 38 (9.4%) were
spinal brucellosis. Of these patients, seven patients
excluded from the study for different reasons (three
patients' therapy was changed by other institution, two
patients had adverse reactions, two died because of under-
lying disease). Thirty-one patients were evaluated in the
study. Seventeen (55%) patients were male and 14 (45%)
patients were female. The average age was 54.2 ± 17.0
years (range 16–83). Twenty-eight (90%) patients had a
history of ingestion of raw milk products and nine (29%)
patients had occupational exposure. Brucellosis was acute
in 11 patients, subacute in 19 patients and chronic in one
patient. The most common symptoms were back pain
(90%), malaise (87%) and arthralgia (87%). Only nine
patients were hospitalised at the beginning of the therapy,
others were followed up in outpatient clinic. Twenty
(65%) patients complained about fever, however only
four (13%) patients had fever on physical examination.
And only three (9.7%) patients had hepatomegaly and
one (3%) patient had splenomegaly. Laseque test was
positive in 13 patients. Cauda equina syndrome was pos-
itive in one patient and severe weakness of muscle in two
patients.
Fifteen patients were included in DS group, whereas 16
patients were included in CR group. The demographic and
clinical variables of the patients at baseline in the two
groups are seen in Table 2. The median age was higher in
CR group than DS group (p = 0.007). However there was
no difference in gender, occupational exposure was more
prevalent in CR group. Furthermore, the duration of
symptoms before therapy was not significantly different
in both groups (p = 0.768). Twelve week drug-cost was 42
Euro in DS and 50 Euro in CR group in our country.
Laboratory findings
The most common laboratory finding was elevated CRP
(n = 21, 67.7%) and elevated ESR (n = 19, 61%). Anaemia
(haemoglobin <12 mg/dl in female, <14 mg/dl in male)
was found in 11 patients and leukocytosis (>10 000/
mm3) in two patients. Leukopenia and thrombocytopeniaPage 4 of 10
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enzymes was found in two patients.
Laboratory findings of the patients at baseline in the two
groups are shown in Table 3. The median ESR was signif-
icantly higher in CR group before treatment (p = 0.049).
However it was not significantly different (p = 0.321),
CRP was higher in CR group. Also CRP declined after
treatment in the both group.
Brucella agglutination titer was ranging between 1/160
and 1/2560) in all patients and there was no difference in
the two groups. However, blood cultures were taken in 26
patients and positive only in four (15.4%) patients in CR
group. Positive blood culture was more prevalent in CR
group.
Radiological findings
As radiological findings, 42 levels of spinal column were
involved in 31 patients. The most common affected site
was lumbar spine (n = 32, 76%), followed by thoracic
spine (n = 6, 14%), sacroiliac joint (n = 3, 8%) and cervi-
cal spine (n = 1, 2%). Involvement level was not different
in two groups. Twenty-two (71%) patients had involve-
ment of only a single spinal region (nine in DS group, 13
in CR group), whereas five (16%) patients had contiguous
involvement at multiple sites (four in DS group, one in
CR group) and four (12.1%) patients had noncontiguous
multifocal involvement (two in DS group, two in CR
group). Furthermore, 13 (39.3%) patients had abscess for-
mation with vertebral involvement (four patients in DS
group and nine patients in CR group). Four (13%)
patients had spinal instability due to collapse of vertebral
body (Table 4).
Treatment and outcome
Two patients discontinued the ciprofloxacin therapy
because of dizziness and switched to doxcycline plus
rifampicin therapy. No adverse effect was observed in DS
group. All the patients had at least 12 weeks antibiotic
therapy and bed rest at least two weeks in the both group.
Lumbosacral orthosis was suggested to the patients with
pain due to instability until resolving symptoms of insta-
bility. The median duration of antibiotic therapy was 12
weeks (range 12–24 weeks) in all patients. However ther-
apeutic failure was not observed in any of these patients,
11 patients' therapy was prolonged due to partial clinical
and radiological improvement. In DS group, the duration
of the therapy was 12 weeks in eight patients, 14 weeks in
three patients, 16 weeks in three patients and 24 weeks in
one patient and the mean duration was 14.0 ± 3.2
(median = 12, range 12–24). On the other hand, in CR
group the duration of the therapy was 12 weeks in 12
patients, 14 weeks in one patient, 16 weeks in two
patients and 20 weeks in one patient and the mean dura-
tion was 13.1 ± 2.3 (median = 12, range 12–20) (Table 4).
The duration of antibiotic therapy was not significantly
different in both groups (p = 0.3519).
Eight (25.8%) patients underwent surgical intervention.
Five of them underwent operation at the first week of the
antibiotic therapy (two for instability -figure 3-, one for
cauda equina syndrome, two for severe weakness of mus-
cle) and these patients were all in CR group. On the other
hand, three of the patients underwent operation after anti-
biotic therapy. Two of these patients were in DS group and
one of them was operated for instability at the end of the
20 weeks therapy, the other one had 16 weeks therapy and
operated three months after the therapy for instability.
The other patient was in CR group and operated at the end
of 16 weeks therapy for instability.
Table 1: Checklist for the diagnosis of clinical instability in the 
lumbar spine
Element Point value
Anterior elements destroyed or unable to function 2
Posterior elements destroyed or unable to function 2
Radiographic criteria 4
Flexion-extension radiographs
Sagital plan translation >4.5 mm or 15% (2pt)
Relative sagittal plane angulation >22 degress 
(2pt)
Cauda equine damage 3
Dangerous loading anticipated 1
Table 3: Forty-two vertebral level involvement in 31 patients in 
the two groups
Characteristic of involvement DS (n = 15) CR (n = 16)
Multifocal involvement (%) 6 (40) 3 (22)
Abscess formation (%) 4 (26.7) 9 (50)
Vertebral level
Cervical spine (n = 1) 1
C5-6 1
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observed in 30 patients. However, of these 30 patients, 24
patients (11 in DS group, 13 in CR group) defined mild
pain at the end of the therapy. One patient who had oper-
ation for instability before and after the therapy defined
moderate pain. Furthermore, physical examination find-
ings improved in most of the patients and Laseque test
was positive only in four patients. All patients underwent
control MRI at the end of the therapy and MRI findings all
improved. Patients were phoned 12 months later the ther-
apy and asked about symptoms or signs of the disease. If
any symptoms or signs were described, they examined
again for motor or sensorial deficit. Relapse was not
observed in the both groups, but sequela was observed in
20 (64.5%) patients (nine in DS group, 11 in CR group).
The development of sequelae was not significantly differ-
ent in the two groups (p = 0.716, × 2 = 0.0178) (Table 4).
Discussion
Spinal brucellosis is one of the most common complica-
tion of human brucellosis in endemic regions [1,9]. In
this study its incidence was 9.4% and it was 12.3% in our
previous study [4]. Ingestion of unpasteurized dairy prod-
ucts (raw milk, butter, cheese) is the most common source
of infection [1] and 90% of our patients had a history of
ingestion of raw milk and products. Furthermore, brucel-
losis has been accepted an occupational disease and con-
sequently male gender are frequently affected [1]. In our
study each sex is affected similarly. High incidence of
ingestion of raw milk products can explain this equiva-
lence.
The symptoms of spinal brucellosis may be insidious and
non-specific, especially in subacute and chronic forms
[1,9]. In our study, subacute form was more common and
back pain, malaise, and arthralgia were the most common
complaints. Fever is another common clinical manifesta-
tion in spinal brucellosis and undulant fever is described
in untreated patients [1,23]. However, 65% of our
patients complained about fever, only four patients had
fever on physical examination. Since most of our patients
were followed up in outpatient clinic, fever may be over-
looked in our study.
The diagnosis of spinal brucellosis is very important for
the duration of antibiotics but early diagnosis is difficult.
Since the early radiological signs of spinal brucellosis are
non-specific and may appear late after the onset of symp-
toms [24]. The appearance of destructive changes on
direct radiographs is about three months and computed
tomography may not be always helpful in the differential
diagnosis from other degenerative diseases and disc herni-
ation [7,25]. MRI is the most useful method for diagnosis,
assessment and management of spinal brucellosis. Also it
has high sensitivity for differential diagnosis and identify-
ing extent of brucellar spondylitis [26]. Consequently,
MRI was used for the diagnosis and assessment in this
study. Spinal involvement was observed in forty-one lev-
els and lumbar spine was the most common involved site,
particularly L4-L5 and L5-S1 in our patients, as reported in
previous studies [2-7]. Moreover, multiple site involve-
ment can be seen and the reported incidence was 9% in
the previous studies [2,7]. In our study, multifocal
involvement was 30.3% and, moreover, four patients had
non-contiguous involvement at multiple sites. Abscess
formation has been rarely reported in the past [7], but in
recent years, with highly sensitive diagnostic techniques, it
becomes a common finding (21%) [6], as in this study
(42%). Sacroiliitis is one of the most common form of
osteoarticular involvement [4,5], however only 9% of our
patients had sacroiliitis.
Despite its frequency in developing countries, the optimal
treatment regimen is still controversial. The combination
of tetracycline/doxycycline and streptomycin is accepted
by the World Health Organization (WHO) as the treat-
ment of choice for spinal brucellosis [1]. However, the
reported success rate with this classical regimen is 60%–
90%. Moreover, therapeutic failure and relapse rates are
still common [2,7]. In our previous report, the relapse rate
in osteoarticular involvement was 12.1% and the highest
relapse rate was in tetracycline+streptomycin group
(14.3%) [4]. Also, the inconvenience of intramuscular
streptomycin administration and the toxicity of tetracy-
cline/doxycycline limited the adaptation of patients. The
second alternative regimen, the combination of rifampin-
doxycycline, has been shown to be less effective than dox-
cycline-streptomycin [11,12]. As a result, alternative regi-
mens are investigated in recent years. Quinolones are the
most commonly studied antibiotics because of their good
bactericidal activity and penetration into leukocytes and
macrophages. However, monotherapy with these antibi-
otics showed high relapse rates [27,28], combination reg-
imens with rifampin were found as effective as doxcycline
plus rifampin [17,18]. To our knowledge, combination
regimens including quinolones were not compared with
the classical regimen, doxcycline-streptomycin, in spinal
brucellosis. Because of their success in bone infections,
they can be alternative as oral regimen to doxcycline-
streptomycin therapy in spinal brucellosis. The aim of this
study was to compare quinolone-rifampicin efficacy in
spinal brucellosis with doxcycline-streptomycin. How-
ever, there were differences between the both groups,
(patients in CR group were older, the median ESR and
CRP were higher at baseline, abscess formation and oper-
ation indication before therapy were more prevalent in
this group and multifocal involvement was more preva-
lent in DS group), the outcome was not different in the
two groups. Therapeutic failure wasn't observed in the two
treatment groups.Page 6 of 10
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controversial. As relapse rate and therapeutic failure were
significantly higher in shorter durations [1,9], the dura-
tion of antibiotics was at least 12 weeks in our study. It
was prolonged according to the resolution of clinical and
MRI findings. There was no difference in median duration
(12 weeks) of therapy in the both groups. In the compar-
ison of the adverse effects, no adverse effect was observed
in DS group and two patients in CR group stopped the
treatment because of dizziness. Relapse was not observed
in any patient after one year of the therapy. Probably, this
is the result of appropriate duration of antibiotics.
Table 2: Clinical characteristics of 31 patients at baseline in the two groups
Characteristic DS (n = 15) CR (n = 16)
Median age [yr] (range) 48 (16–65) 68 (25–83)
Male (%) 9 (60) 8 (50)
Brucellosis risk factor
Occupational exposure (%) 1 (6.7) 8 (44.4)
Ingestion of unpasteurized dairy 
products (%)
14 (93.3) 14 (87.5)
Duration of symptoms before therapy 
(weeks)
Mean ± SD 14.9 ± 13.0 15.3 ± 12.0
Median (range) 12 (2–40) 14 (2–48)
Operation before therapy n (%) 0 5 (31)
Symptoms n (%) n (%)
Malaise 12 (80) 15 (94)
Back pain 14 (93) 14 (88)
Arthralgia 13 (87) 14 (88)
Sweating 11 (73) 15 (94)
Anorexia 7 (47) 15 (89)
Fever 9 (60) 11 (69)
Myalgia 9 (60) 11 (69)
Nausea 4 (27) 5 (31)
Abdominal pain 2 (13) 5 (31)





Laseque test positivity 5 8
Clinical spectrums (duration of 
symptoms)
Acute (<8 weeks) 6 5
Subacute (8–52 weeks) 9 10
Chronic (>52 weeks) 0 1
Patients hospitalised 3 6
Laboratory findings of 31 patients at baseline in the two groups
Laboratory finding DS (n = 15) (%) CR (n = 16) (%)
Anemia 4 (27) 7 (44)
Leucocytosis 0 2 (13)
Median ESR 22 (3–110) 54 (2–88)
Median CRP
Before therapy 33 (3–151) 53 (3–140)
After therapy 3 (3–5) 5 (3–14)
Median agglutination titer (range) 320 (160–2560) 320 (160–1280)
Positive blood culture (%) 0 4 (22)Page 7 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2006, 6:72 http://www.biomedcentral.com/1471-2334/6/72The diagnostic or curative surgery can be performed in spi-
nal brucellosis but it is last option in the management of
spinal brucellosis. The indications for surgery are; spinal
instability, cauda equina syndrome, severe weakness of
muscle due to extradural inflammatory mass or progres-
sive collapse [6,7]. Eight patients in our study underwent
operation and the most common indication for surgery
was instability. The need for operation after therapy was
not different in the both treatment group. Abscess drain-
age is not always needed in the absence of neurological
deterioration [7] and only one of our patients underwent
abscess drainage for neurological deficit; others all
improved with medical management.
A delayed convalescence after treatment is the well-known
clinical sequela in spinal brucellosis. The reason can't be
understood, but pscychoneurosis exacerbated by the
infection is believed to be a reason for the delay [1]. Mild
clinical sequela was observed equally in the both group
one year after the therapy. Only one patient in CR group
who had operation before and after the therapy had mod-
erate sequale.
The reported disadvantage of quinolone including is the
high cost rates [18,19]. In this study we only calculated
the drug cost for the median duration (12 weeks) of the
both group and the cost of CR therapy was 1.2 fold higher
than the cost of DS therapy.
Conclusion
Ciprofloxacin-rifampicin regimen is as effective as classi-
cal regimen. Despite the disadvantages (older age, more
prevalent operation and abscess formation before the
therapy) of the patients in CR group, the duration of the
therapy and clinical response were not different from the
classical regimen. So combination of ciprofloxacin and
rifampin can be an alternative regimen in spinal brucello-
sis. However it can't be considered as first-line therapy
because of its high cost that is important for developing
countries. Classical regimen (doxycycline with streptomy-
cin), with the appropriate duration (at least 12 weeks), is
still the first line antibiotics and alternative therapies
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